Bank of Montreal’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.3M | Buy |
515,981
+653
| +0.1% | +$26.7K | 0.01% | 783 |
|
|
2026
Q1 | $17.1M | Buy |
515,328
+2,950
| +0.6% | +$87.9K | 0.01% | 900 |
|
|
2025
Q4 | $15.3M | Sell |
512,378
-237
| -0% | -$7.74K | 0.01% | 952 |
|
|
2025
Q3 | $18.5M | Sell |
512,615
-12,629
| -2% | -$416K | 0.01% | 812 |
|
|
2025
Q2 | $18.9M | Buy |
525,244
+769
| +0.1% | +$28.6K | 0.01% | 745 |
|
|
2025
Q1 | $20.7M | Buy |
524,475
+504,459
| +2,520% | +$17M | 0.01% | 698 |
|
|
2024
Q4 | $602K | Buy |
20,016
+1,357
| +7% | +$38.9K | ﹤0.01% | 2120 |
|
|
2024
Q3 | $445K | Buy |
+18,659
| New | +$408K | ﹤0.01% | 2501 |
|
|
2024
Q2 | – | Sell |
-48,675
| Closed | -$877K | – | 4242 |
|
|
2024
Q1 | $877K | Buy |
+48,675
| New | +$775K | ﹤0.01% | 2077 |
|
|
2023
Q3 | – | Sell |
-127,933
| Closed | -$3.29M | – | 4230 |
|
|
2023
Q2 | $3.29M | Buy |
127,933
+11,704
| +10% | +$302K | ﹤0.01% | 1543 |
|
|
2023
Q1 | $1.75M | Sell |
116,229
-125,602
| -52% | -$1.91M | ﹤0.01% | 1746 |
|
|
2022
Q4 | $2.86M | Buy |
241,831
+154,979
| +178% | +$1.12M | ﹤0.01% | 1618 |
|
|
2022
Q3 | $546K | Buy |
86,852
+3,401
| +4% | +$22.3K | ﹤0.01% | 2535 |
|
|
2022
Q2 | $366K | Buy |
83,451
+193
| +0.2% | +$1.21K | ﹤0.01% | 2885 |
|
|
2022
Q1 | $820K | Buy |
83,258
+5,481
| +7% | +$63.4K | ﹤0.01% | 2495 |
|
|
2021
Q4 | $1.53M | Sell |
77,777
-799
| -1% | -$20.7K | ﹤0.01% | 1725 |
|
|
2021
Q3 | $2.65M | Sell |
78,576
-432
| -0.5% | -$13.4K | ﹤0.01% | 1934 |
|
|
2021
Q2 | $3.12M | Buy |
79,008
+72,303
| +1,078% | +$2.84M | ﹤0.01% | 1828 |
|
|
2021
Q1 | $313K | Sell |
6,705
-13,055
| -66% | -$627K | ﹤0.01% | 2907 |
|
|
2020
Q4 | $1.04M | Buy |
19,760
+14,505
| +276% | +$490K | ﹤0.01% | 2219 |
|
|
2020
Q3 | $151K | Sell |
5,255
-2,966
| -36% | -$68.3K | ﹤0.01% | 2862 |
|
|
2020
Q2 | $198K | Buy |
+8,221
| New | +$132K | ﹤0.01% | 2742 |
|
|
2020
Q1 | – | Sell |
-11,547
| Closed | -$128K | – | 4680 |
|
|
2019
Q4 | $128K | Buy |
11,547
+3,120
| +37% | +$23.7K | ﹤0.01% | 3389 |
|
|
2019
Q3 | $47K | Buy |
8,427
+284
| +3% | +$1.98K | ﹤0.01% | 3652 |
|
|
2019
Q2 | $70K | Buy |
8,143
+7,475
| +1,119% | +$56.5K | ﹤0.01% | 3531 |
|
|
2019
Q1 | $5K | Sell |
668
-211
| -24% | -$1.14K | ﹤0.01% | 4039 |
|
|
2018
Q4 | $4K | Buy |
879
+443
| +102% | +$2.2K | ﹤0.01% | 4185 |
|
|
2018
Q3 | $2K | Sell |
436
-84
| -16% | -$960 | ﹤0.01% | 4396 |
|
|
2018
Q2 | $7K | Buy |
520
+420
| +420% | +$5.78K | ﹤0.01% | 4060 |
|
|
2018
Q1 | $1K | Hold |
100
| – | – | ﹤0.01% | 4108 |
|
|
2017
Q4 | $1K | Buy |
+100
| New | +$874 | ﹤0.01% | 4110 |
|
|
2017
Q2 | – | Sell |
-38,000
| Closed | -$443K | – | 4290 |
|
|
2017
Q1 | $443K | Buy |
+38,000
| New | +$273K | ﹤0.01% | 2140 |
|
|
2016
Q2 | – | Sell |
-324
| Closed | -$3K | – | 4314 |
|
|
2016
Q1 | $3K | Sell |
324
-567
| -64% | -$4.96K | ﹤0.01% | 3925 |
|
|
2015
Q4 | $11K | Buy |
+891
| New | +$11.3K | ﹤0.01% | 3602 |
|
|
2014
Q3 | – | Sell |
-460
| Closed | -$4K | – | 4389 |
|
|
2014
Q2 | $4K | Sell |
460
-10,340
| -96% | -$66.1K | ﹤0.01% | 4280 |
|
|
2014
Q1 | $75K | Buy |
+10,800
| New | +$63.9K | ﹤0.01% | 2932 |
|
Other funds holding TGTX
SCM
CAM
Bank of Montreal's TGTX Position: Q2 2026 in Review
Bank of Montreal increased its TG Therapeutics (TGTX) stake by 0.13% in Q2 2026, buying an estimated $26.7K and bringing the position to 515,981 shares worth $28.3M. The position accounts for 0.01% of the portfolio, ranked #783.
Bank of Montreal first reported a position in TGTX in Q1 2014 and has held it in 36 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.
- Bank of Montreal held 515,981 shares of TG Therapeutics worth $28.3M as of Q2 2026.
- Bank of Montreal bought 653 TG Therapeutics shares in Q2 2026, an estimated $26.7K.
- TG Therapeutics made up 0.01% of Bank of Montreal's portfolio in Q2 2026, its #783 holding.
- Bank of Montreal first reported a position in TG Therapeutics in Q1 2014 and has held it in 36 quarters since.
- 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.
Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.